Drug resistance and BCR-ABL kinase domain mutations in philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement

Simona Sica, Simona Soverini, Caterina De Benedittis, Cristina Papayannidis, Stefania Paolini, Claudia Venturi, Ilaria Iacobucci, Mario Luppi, Paola Bresciani, Marzia Salvucci, Domenico Russo, Ester Orlandi, Tamara Intermesoli, Antonella Gozzini, Massimiliano Bonifacio, Gian Matteo Rigolin, Fabrizio Pane, Michele Baccarani, Michele Cavo, Giovanni Martinelli

Risultato della ricerca: Contributo in rivistaArticolo in rivista

77 Citazioni (Scopus)

Abstract

Patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) frequently relapse on imatinib with acquisition of BCR-ABL kinase domain (KD) mutations. To analyze the changes that second-generation tyrosine kinase inhibitors (TKIs) have brought in mutation frequency and type, a database review was undertaken of the results of all the BCR-ABL KD mutation analyses performed in the authors' laboratory from January 2004 to January 2013.
Lingua originaleEnglish
pagine (da-a)N/A-N/A
RivistaCancer
Volume2013
DOI
Stato di pubblicazionePubblicato - 2013

Keywords

  • BCR-ABL mutations
  • acute lymphoblastic leukemia
  • dasatinib
  • imatinib
  • resistance

Fingerprint Entra nei temi di ricerca di 'Drug resistance and BCR-ABL kinase domain mutations in philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement'. Insieme formano una fingerprint unica.

Cita questo